Thyrocare Q2 FY27 Results: Revenue Rises 25.1%, Net Profit Falls 66.9% to ₹15.89 crore

Thyrocare Technologies reported a 25.1% year-on-year increase in consolidated revenue to ₹270.81 crore in Q2 FY27. However, net profit fell 66.9% to ₹15.89 crore, impacted by a ₹44.98 crore impairment charge related to its subsidiary, Nueclear Healthcare Limited.

Thyrocare Q2 FY27 Financial Results

Financial Metric	Q2 FY27	Q2 FY26
Revenue	₹270.81 crore	₹216.53 crore
EBITDA	₹44.30 crore	₹71.35 crore
EBITDA Margin	16.36%	32.95%
Net Profit	₹15.89 crore	₹47.99 crore

What Drove Thyrocare's Performance?

The company recorded growth in its core diagnostic business, with 5.7 million patients served, up 14%, and 61.6 million tests conducted, up 27% year-on-year. Its franchise network also expanded to 12,911 active franchisees.

However, the ₹44.98 crore impairment charge weighed on consolidated profitability. Thyrocare is also pursuing the proposed sale of its entire stake in Nueclear Healthcare for approximately ₹141.40 crore, subject to shareholder approval.

Thyrocare Share Performance

Period	Return
1 day	-3.77%
5 days	+9.51%
1 month	-5.50%
6 months	+27.86%
1 year	+14.84%
5 years	+36.10%

Key takeaway: Thyrocare's revenue and testing volumes continued to grow, but impairment-related costs significantly reduced reported profit and EBITDA margins.

What were Thyrocare Technologies’ Q2 FY27 results?

Thyrocare Technologies reported consolidated revenue of ₹270.81 crore in Q2 FY27, up 25.1% year-on-year. However, consolidated net profit declined 66.9% to ₹15.89 crore, partly due to a ₹44.98 crore impairment loss on its investment in Nueclear Healthcare Limited.

Why did Thyrocare’s net profit fall in Q2 FY27?

Thyrocare’s consolidated net profit fell to ₹15.89 crore from ₹47.99 crore in Q2 FY26. A key factor was the ₹44.98 crore impairment loss recognised on its investment in Nueclear Healthcare Limited following a valuation assessment.

What was Thyrocare’s revenue in Q2 FY27?

Thyrocare’s consolidated revenue increased 25.1% year-on-year to ₹270.81 crore, compared with ₹216.53 crore in Q2 FY26. Standalone revenue from operations also grew 26.7% to ₹256.25 crore.

What was Thyrocare’s EBITDA margin in Q2 FY27?

Thyrocare reported consolidated EBITDA of ₹44.30 crore, down 37.9% year-on-year. Its EBITDA margin declined to 16.36% from 32.95% in Q2 FY26.

What was Thyrocare’s profit before exceptional items in Q2 FY27?

Thyrocare reported profit after tax before exceptional items of ₹60.2 crore, up 25.7% year-on-year, with an EBITDA margin of approximately 33%. This measure provides additional context on operating performance alongside the reported consolidated net profit.

Why is Thyrocare planning to sell Nueclear Healthcare?

Thyrocare is pursuing the sale of its entire shareholding in Nueclear Healthcare for approximately ₹141.40 crore, subject to shareholder approval. The proposed exit is intended to help Thyrocare focus more closely on its pathology business, which reported a ROCE of 34.91%, compared with 6.95% for Nueclear Healthcare.

How did Thyrocare’s diagnostic business perform in Q2 FY27?

Thyrocare served 5.7 million patients, up 14% year-on-year, and conducted 61.6 million tests, up 27%. Revenue per patient increased 9.8% to ₹433, while its active franchisee network reached 12,911.

What should investors watch after Thyrocare’s Q2 FY27 results?

Investors may monitor diagnostic revenue growth, patient and test volumes, EBITDA margin recovery and progress on the proposed Nueclear Healthcare divestment. The key consideration is whether Thyrocare can sustain business growth while improving reported profitability and managing its cash position.